Table 2.
Patient Characteristics (N=79)
| Variable | Value |
|---|---|
|
| |
| Age – mean (range) | 73 (65–90) |
|
| |
| Race | |
| White | 69(87%) |
| Black or African-American | 8 (10%) |
| Native Hawaiian or Pacific Islander | 1 (1%) |
| Native Indian or Alaskan Native | 1 (1%) |
|
| |
| Gender | |
| Male | 41 (52%) |
| Female | 38 (48%) |
|
| |
| Education | |
| More than high school | 27 (34%) |
| High school graduate or less | 52 (66%) |
|
| |
| Marital Status | |
| Not Married | 38 (49%) |
| Married | 40 (51%) |
| Unknow | 1 |
|
| |
| Living Alone | |
| No | 49 (68%) |
| Yes | 23 (32%) |
| Unknown | 7 |
|
| |
| Body Mass Index (BMI) – mean (range) | 27 (15–49) |
| Underweight (BMI <18.5) | 1 (1%) |
| Normal weight (BMI 18.5 to <25) | 28 (35%) |
| Overweight (BMI 25 to <30) | 31 (39%) |
| Obese (BMI 30 or higher) | 17 (22%) |
| Unknown | 2 (3%) |
|
| |
| Clinical Diagnosis | |
|
| |
| Small Cell Lung Cancer | 5 (6%) |
| Limited | 3 |
| Extensive | 2 |
|
| |
| Non-Small Cell Lung Cancer | 66 (84%) |
|
| |
| Adenocarcinoma | 47 |
|
| |
| Squamous Cell Cancer | 16 |
|
| |
| Large Cell Carcinoma | 1 |
|
| |
| Mixed Histology | 2 |
|
| |
| Missing histology/unspecified histology | 8 (10%) |
|
| |
| Stage at diagnosis | |
| 1 | 11 (14%) |
| 2 | 6 (8%) |
| 3 | 19 (24%) |
| 4 | 32 (41%) |
| Unknown | 11 (14%) |
|
| |
| Metastasis sites | |
| Bone | 11 (14%) |
| Brain | 13 (16%) |
| Both | 4 (5%) |
|
| |
| Assessments and Questionnaires | |
|
| |
| Social Support-Emotional Score (range 0–100) – score <50 (“lower” support) | 5 (6%) |
|
| |
| Social Support-Tangible Score (range 0–100) -- score <50 (“lower” support) | 5 (6%) |
|
| |
| Treatment stage when the Geriatric Assessment was conducted | |
| Pre-treatment | 48 (61%) |
| During treatment | 17 (22%) |
| Post treatment | 14(18%) |
|
| |
| Karnofsky Performance Status (KPS <80) | 19 (24%) |
|
| |
| Timed Up and Go test -- more than 14 seconds | 34 (43%) |
|
| |
| Patient-Reported Karnofsky Performance Status (<80) | 25 (32%) |
|
| |
| Falls in past 6 months -- 1 or more | 18 (23%) |
|
| |
| Physical Function -- <20 (“lower” function) | 73 (96%) |
|
| |
| Instrumental Activities of Daily Living/IADL -- <14 (some limitations) | 42 (54%) |
|
| |
| Social Activity Limit Score (range 0–100) -- <50 (“lower” activity) | 25 (32%) |
|
| |
| Mental Health Index (MHI)-Depressed (range 0–43) – Depressed (score >12) | 19 (28%) |
|
| |
| Mental Health Index (MHI)-Anxious (range 0–20) – Anxious (score >=6) | 26 (35%) |
|
| |
| Treatment | |
|
| |
| Surgery: yes | 34 (43%) |
| Unknown | 8 (10%) |
|
| |
| Radiation: yes | 54 (68%) |
| Unknown | 5 (6%) |
|
| |
| Clinical Trial: Yes | 26 (33%) |
| Unknown | 19 (24%) |
|
| |
| Treatment Goal | |
| Palliative Care | 44 (56%) |
| Curative | 27 (20%) |
| Unknown | 8 (10%) |
|
| |
| Number of Prior Regimens Started | |
| 0 | 17 (22%) |
| 1 | 36 (46%) |
| 2 | 9 (11%) |
| 3 | 8 (10%) |
| 4 | 9 (11%) |
|
| |
| Chemotherapy treatment ever received – can be more than one treatment | |
| Single-Agent Chemotherapy | 26 (42%) |
| Platinum-Based Doublet | 37 (47%) |
| Doublet Therapy without Platinum | 2 (3%) |
| Platinum-Based Doublet with Biologic | 8 (10%) |
| Platinum Doublet with Immunotherapy | 13 (16%) |
|
| |
| Chemotherapy – yes | 62 (78%) |
| Unknown | 5 (6%) |
|
| |
| Completed Planned Cycles of Chemotherapy – yes | 22 (28%) |
| Unknown | 23 (29%) |
|
| |
| Treated with Immunotherapy – yes | 6 (8%) |
| Unknown | 17 (22%) |
|
| |
| Completed Planned Cycles of Immunotherapy -- yes | 3 (50%) |
|
| |
| Given Oral Targeted Therapy – yes | 34 (43%) |
| Unknown | 7 (9%) |
|
| |
| Adverse Events During Treatment | |
|
| |
| Hospitalized -- yes | 36 (46%) |
|
| |
| Dose reduction – yes | 23 (29%) |
|
| |
| Treatment Delay – yes | 19 (24%) |
|
| |
| Early treatment Discontinuation -- yes | 32 (41%) |
|
| |
| Patient Status at the time of Data Entry | |
|
| |
| Deceased | 48 (61%) |
|
| |
| No Evidence of Disease | 8 (10%) |
|
| |
| Disease Progression | 7 (9%) |
|
| |
| Unknown | 16 (20%) |